Literature DB >> 12296867

Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3.

N Matsushita1, M Kashiwagi, R Wait, R Nagayoshi, M Nakamura, T Matsuda, P Hogger, P M Guyre, H Nagase, T Matsuyama.   

Abstract

The aim of the present study was to evaluate levels of soluble CD 163 in sera and fluids from rheumatoid arthritis (RA) patients and elucidate the mechanism that regulates the shedding of CD163. Levels of soluble CD163 in sera and fluids from RA patients were examined by a sandwich enzyme immunoassay and Western blotting. To determine the effects of tissue inhibitors of metalloproteinase (TIMPs) on the shedding of CD163 from monocytes/macrophages, levels of soluble CD163 in cultures of monocytes/macrophages and the expression of CD163 on monocytes/macrophages in the presence or absence of TIMPs were examined by a sandwich enzyme immunoassay and flow cytometry, respectively. The clinical marker that was most associated with serum levels of soluble CD163 was levels of CRP. TIMP-3, but not TIMP-1 or TIMP-2, inhibited the shedding of CD163 from monocytes/macrophages. It was shown that serum levels of soluble CD163 are a sensitive and reliable marker to monitor activated macrophages in synovitis from RA patients and the results imply that the responsible proteinase for the shedding of CD163 is not a member of the matrix metalloproteinases, but is likely to be a member of ADAMs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12296867      PMCID: PMC1906487          DOI: 10.1046/j.1365-2249.2002.01963.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).

Authors:  M Kashiwagi; M Tortorella; H Nagase; K Brew
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

2.  Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; H Ishida; M Shimizu; M Suemura; R McCloskey; T Kishimoto
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

3.  Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis.

Authors:  I Torsteinsdóttir; L Hâkansson; R Hällgren; B Gudbjörnsson; N G Arvidson; P Venge
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

4.  Interaction of CD163 with the regulatory subunit of casein kinase II (CKII) and dependence of CD163 signaling on CKII and protein kinase C.

Authors:  M Ritter; C Buechler; M Kapinsky; G Schmitz
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

5.  Identification of the haemoglobin scavenger receptor.

Authors:  M Kristiansen; J H Graversen; C Jacobsen; O Sonne; H J Hoffman; S K Law; S K Moestrup
Journal:  Nature       Date:  2001-01-11       Impact factor: 49.962

6.  Human monocytes express CD163, which is upregulated by IL-10 and identical to p155.

Authors:  T H Sulahian; P Högger; A E Wahner; K Wardwell; N J Goulding; C Sorg; A Droste; M Stehling; P K Wallace; P M Morganelli; P M Guyre
Journal:  Cytokine       Date:  2000-09       Impact factor: 3.861

7.  Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.

Authors:  M Frosch; A Strey; T Vogl; N M Wulffraat; W Kuis; C Sunderkötter; E Harms; C Sorg; J Roth
Journal:  Arthritis Rheum       Date:  2000-03

8.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Authors:  P Charles; M J Elliott; D Davis; A Potter; J R Kalden; C Antoni; F C Breedveld; J S Smolen; G Eberl; K deWoody; M Feldmann; R N Maini
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

9.  Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts.

Authors:  M Takizawa; E Ohuchi; H Yamanaka; H Nakamura; E Ikeda; P Ghosh; Y Okada
Journal:  Arthritis Rheum       Date:  2000-04

10.  Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.

Authors:  M L Fitzgerald; Z Wang; P W Park; G Murphy; M Bernfield
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

View more
  32 in total

1.  Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection.

Authors:  Rebeccah A McKibben; Joseph B Margolick; Steven Grinspoon; Xiuhong Li; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Richard T George; Lisa P Jacobson; Matthew Budoff; Russell P Tracy; Todd T Brown; Wendy S Post
Journal:  J Infect Dis       Date:  2014-10-30       Impact factor: 5.226

2.  Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease.

Authors:  Abdulselam Ilter; Cihan Orem; Fulya Balaban Yucesan; Mursel Sahin; Yusuf Hosoglu; Elif Kurumahmutoglu; Serap Ozer Yaman; Asim Orem
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure.

Authors:  Hong Ye; Li-Yuan Wang; Jing Zhao; Kai Wang
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

4.  Evidence for M2 macrophage activation in patients with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Shruti Bhattacharya; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

5.  Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives.

Authors:  Silke Ryan
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

6.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

7.  Association between the haptoglobin and heme oxygenase 1 genetic profiles and soluble CD163 in susceptibility to and severity of human malaria.

Authors:  Vitor R R Mendonça; Nívea F Luz; Nadja J G Santos; Valéria M Borges; Marilda S Gonçalves; Bruno B Andrade; Manoel Barral-Netto
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

8.  Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis.

Authors:  Claudia Jude; Doru Dejica; Gabriel Samasca; Loredana Balacescu; Ovidiu Balacescu
Journal:  Rheumatol Int       Date:  2012-08-22       Impact factor: 2.631

Review 9.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

10.  Levels of soluble CD163 and severity of malaria in children in Ghana.

Authors:  Kwadwo A Kusi; Ben A Gyan; Bamenla Q Goka; Daniel Dodoo; George Obeng-Adjei; Marita Troye-Blomberg; Bartholomew D Akanmori; Jonathan P Adjimani
Journal:  Clin Vaccine Immunol       Date:  2008-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.